Sari A, et al. - This study offers information on the efficacy of rituximab as a treatment strategy for patients with long-standing systemic sclerosis-associated interstitial lung disease (SSc-ILD). Most SSc patients with longer disease duration and worse pulmonary function exhibited improvement or stabilization of pulmonary disease as a result of being treated with rituximab. Overall, rituximab might be useful in this patient group who is resistant to conventional immunosuppressive treatments.